The Duchenne muscular dystrophy (DMD) landscape across the seven major markets (7MM) - the US, France, Germany, Italy, Spain, ...

The US Food and Drug Administration approved Sarepta’s Exondys 51 (eteplirsen) injection, making it the first drug available for the rare genetic muscle-wasting disease in the country.

Legal Automation Systems, Inc., doing business as eFileMadeEasy, a leader in automated court eFiling solutions, is proud to announce its selection by the Arizona Supreme Court as a significant, next ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2024 financial ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2024 financial results after the Nasdaq Global Market ...

Deutsche Bank analyst David Hoang initiated coverage of Sarepta (SRPT) with a Hold rating and $136 price target Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover ...

Sarepta Therapeutics, Inc. has a fifty-two week low of $102.15 and a fifty-two week high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84.

Sarepta Therapeutics has a 12-month low of $102.15 and a 12-month high of $173.25. The stock has a market capitalization of $10.49 billion, a price-to-earnings ratio of 87.85 and a beta of 0.75.

Arrowhead (ARWR) announced that the global licensing and collaboration agreement with Sarepta Therapeutics (SRPT) announced on November 26, 2024, has now closed. Closing of the transaction was ...

Regenerative Medicine Market Growth BURLINGAME, CA, UNITED STATES, February 14, 2025 /EINPresswire / --The global Regenerative Medicin ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...